What are Astellas Pharma Global Development, Inc.'s marketed drugs?

Top marketed products include Tacrolimus immediate release.

Astellas Pharma Global Development, Inc.

1 marketed · 3 in Phase 3

ASP0113 · Immunology / Infectious Disease
ASP0113 is a therapeutic vaccine that stimulates the immune system to recognize and eliminate cells infected with cytomegalovirus (CMV).
enfortumab vedotin (EV) · Oncology
Enfortumab vedotin is a monoclonal antibody-drug conjugate that targets Nectin-4, a protein highly expressed on the surface of certain cancer cells.
LoDAC (Low Dose Cytarabine) · Oncology
Low-dose cytarabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA and blocking cell division, primarily affecting rapidly dividing hematopoietic cells.

ASKP1240 · Oncology
ASKP1240 is a small molecule inhibitor of the PI3Kδ enzyme.
ASP0819 · Immunology
ASP0819 is a small molecule inhibitor of the PI3K delta subunit.
ASP1650 · Oncology
ASP1650 is a selective antagonist of the prostaglandin E receptor EP4, which reduces inflammatory signaling and immune suppression in the tumor microenvironment.
ASP1707 · Immunology
ASP1707 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
ASP2215 · Oncology
ASP2215 is a selective and potent inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase.
ASP4345 · Immunology
ASP4345 is a small molecule inhibitor of the PI3K delta subunit.
ASP5541 · Immunology
ASP5541 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.
IMAB362

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: